BTIG lowered the firm’s price target on Spectral AI (MDAI) to $2 from $3 and keeps a Buy rating on the shares after its Q1 results. The company is appropriately trimming operating spend to preserve cash, though the firm is reducing its price target to reflect a higher share count, the analyst tells investors in a research note. Spectral AI also continues to expect to submit DeepView to the FDA by the end of 2Q25 with approval expected in early FY26, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDAI:
- Spectral AI’s Promising Outlook: Strong Financials, Strategic Expense Management, and Key Milestone Achievements
- Spectral AI Reports Strong Q1 2025 Results
- Spectral AI files to sell 2.84M shares of common stock for holders
- Spectral AI Enhances CFO Compensation Amidst Growth
- Spectral AI’s Promising Future: Buy Rating Backed by Strong Prospects and Strategic Developments